IBI-102

IBI-102 is an investigational **anti-GITR monoclonal antibody** being developed by Innovent as an immuno-oncology therapy for **advanced malignant tumors**. Publicly available pipeline summaries describe it as a **GITR agonist**, indicating that it is intended to activate glucocorticoid-induced tumor necrosis factor receptor-related protein signaling to enhance anti-tumor immune responses, potentially through T-cell co-stimulation and modulation of regulatory T-cell biology. The program appears to have reached **IND approval** in China around 2020, but there is little recent public evidence of later-stage clinical advancement, so the asset appears to remain an early clinical or pre-proof-of-concept oncology program with limited disclosed clinical detail.